--- title: "Ensysce Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 961 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286632542.md" datetime: "2026-05-16T04:10:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286632542.md) - [en](https://longbridge.com/en/news/286632542.md) - [zh-HK](https://longbridge.com/zh-HK/news/286632542.md) --- # Ensysce Biosciences | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 961 K Revenue: As of FY2026 Q1, the actual value is USD 961 K, missing the estimate of USD 1.9 M. EPS: As of FY2026 Q1, the actual value is USD -0.52, beating the estimate of USD -0.73. EBIT: As of FY2026 Q1, the actual value is USD -3.562 M. Ensysce Biosciences, Inc. announced its financial results for the fiscal quarter ended March 31, 2026, as detailed in a press release on May 15, 2026. #### Cash and Cash Equivalents Cash and cash equivalents were $0.7 million as of March 31, 2026, a decrease from $4.3 million as of December 31, 2025. Subsequent to March 31, 2026, Ensysce Biosciences, Inc. secured an additional $2.0 million in convertible preferred stock financing on April 7, 2026. #### Federal Grants Funding from federal grants totaled $1.0 million for the first quarter of 2026, marking a $0.3 million decrease compared to $1.3 million in the comparable year-ago quarter. #### Operating Expenses Research & Development (R&D) expenses increased by $1.4 million to $3.3 million for the first quarter of 2026, up from $1.9 million for the same period in 2025. General & Administrative (G&A) expenses decreased by $0.2 million to $1.2 million in the first quarter of 2026, from $1.4 million for the first quarter of 2025. Total operating expenses for Q1 2026 were $4,523,229, an increase from $3,287,284 for Q1 2025. #### Net Loss Net loss attributable to common stockholders for the first quarter of 2026 was -$3.6 million, compared to a net loss of -$1.9 million for the first quarter of 2025. The reported net loss for Q1 2026 was -$3,556,415, in contrast to -$1,945,573 for Q1 2025. Net loss per share, basic and diluted, was -$0.52 for Q1 2026, compared to -$1.39 for Q1 2025. #### Cash Flow Net cash used in operating activities was -$3,500,925 for Q1 2026, compared to -$1,707,412 for Q1 2025. Net cash used in financing activities was -$63,947 for Q1 2026, a decrease from $1,257,826 provided by financing activities for Q1 2025. Cash and cash equivalents at the end of the period were $745,482 for Q1 2026, compared to $3,052,491 for Q1 2025. #### Operational Highlights Ensysce Biosciences, Inc. achieved 50% of the interim enrollment target in its pivotal PF614-301 Phase 3 trial and secured Institutional Review Board (IRB) approval to initiate Part 3 of PF614-MPAR-102, the final stage of that study. The company also expanded its patent estate across both its opioid and ADHD programs and published the first peer-reviewed clinical data validating its MPAR® overdose-protection technology. #### Outlook / Guidance Ensysce Biosciences, Inc.’s Board has initiated a formal review of strategic alternatives, including potential partnerships and licensing opportunities, to accelerate platform development and unlock shareholder value. The company anticipates continued research and development efforts towards regulatory approvals for its product candidates will result in losses for the foreseeable future. IRB approval for Part 3 of PF614-MPAR-102, secured post-quarter, is expected to strengthen clinical evidence for overdose risk management. ### Related Stocks - [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md) ## Related News & Research - [Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21](https://longbridge.com/en/news/286613093.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)